Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
Clinical considerations of hyaluronidase as an adjunct to subcutaneous rituximab injection
Mário L de Lemos1, Anne Dar Santos1
1Provincial Pharmacy, Systemic Therapy Program, BC Cancer, Vancouver, BC, Canada.
Subcutaneous rituximab injectables are formulated with recombinant human hyaluronidase as an adjunct to facilitate the absorption of the large volume of rituximab. We review the clinical considerations regarding the potential for systemic hyaluronidase toxicity and increased systemic absorption of subcutaneous or topical drugs administered subsequent to rituximab.
Subcutaneous rituximab injectables are formulated with recombinant human hyaluronidase as an adjunct to facilitate the absorption of the large volume of rituximab. We review the clinical considerations regarding the potential for systemic hyaluronidase toxicity and increased systemic absorption of subcutaneous or topical drugs administered subsequent to rituximab.
Related Concept Videos
Design Consideration
The factor of safety is another key...
Heart Failure VI: Adjunct Therapies
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...
Transmission Line Design Considerations
Special considerations while measuring pulse
Energy Considerations in Open Channel Flow

